menu
    • menu
    [{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pemafibrate","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kowa Pharmaceuticals America","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Kowa Pharmaceuticals America \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Pharmaceuticals America \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America"}]

    Find Clinical Drug Pipeline Developments & Deals by Kowa Pharmaceuticals America

    Menu

    Kowa Pharmaceuticals America

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America

                            Details : Through the collaboration, Kowa will leverage its primary care sales force to market and promote Zoryve (roflumilast) to primary care practitioners & pediatricians for all FDA-approved indications.

                            Brand Name : Zoryve

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 29, 2024

                            Lead Product(s) : Roflumilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Arcutis Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan

                            Details : Kowa will develop and commercialize NCX470 (bimatoprost) for lowering intraocular pressure in glaucoma patients under a recent agreement with Nicox.

                            Brand Name : NCX 470

                            Molecule Type : Small molecule

                            Upfront Cash : $3.2 million

                            February 08, 2024

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®...

                            Details : The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.

                            Brand Name : Seglentis

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2022

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kowa To Discontinue K-877 (Pemafibrate) "Prominent" Cardiovascular Outcomes Study

                            Details : K-877 (pemafibrate), a highly potent and selective peroxisome proliferator activator receptor-alpha modulator for treatment of hyperlipidemia in Japan under brand name PARMODIA, will discontinue by DSMB who concluded that primary endpoint was unlikely to...

                            Brand Name : K-877

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kowa Pharmaceuticals America

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Esteve Huayi Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Esteve and Kowa Pharmaceuticals America Enter into an Exclusive License and Commercialization Agreement for Ri...

                            Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.

                            Brand Name : E-58425

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 03, 2021

                            Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Esteve Huayi Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth